Compare Abeona Therapeutics Inc (ABEO) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while iShares 10 20 Year Treasury Bond ETF trades at $98.3. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | TLH | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $105.36 |
52-Week Low | $4.17 | $97.13 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TLH trades at $99.53, down 0.04% on the day, with technical indicators signaling a bearish trend. The stock shows no valuation or profitability metrics in the provided data, but upcoming dividends of $0.41 and $0.36 are scheduled for July 2026. Recent news highlights bond market volatility and Federal Reserve uncertainty, which may impact broader equity sentiment.
The outlook for TLH is cautious due to weak technical momentum and lack of fundamental data. Risks include macroeconomic pressures from potential rate hikes, while the dividend payments offer some income support. Investors should seek updated financials for a clearer assessment of the company's health and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
